GSK India Sales Growth Falters In Battle With Retailers Over Margins
This article was originally published in PharmAsia News
A continuing battle between India retailers and drug makers has led to complaints by GlaxoSmithKline and others of boycotts on some of their products that began in mid-September, leading to reduced sales.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.